Relatlimab and nivolumab in the treatment of melanoma

Lewis Au; James Larkin; Samra Turajlic

doi:10.1016/j.cell.2022.12.003

Relatlimab and nivolumab in the treatment of melanoma

Cell. 2022 Dec 22;185(26):4866-4869. doi: 10.1016/j.cell.2022.12.003.

Authors

Lewis Au¹, James Larkin², Samra Turajlic³

Affiliations

¹ Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, VIC 3010, Australia; Cancer Dynamics Laboratory, The Francis Crick Institute, London NW1 1AT, UK.
² Renal and Skin Units, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK; Melanoma and Kidney Cancer Team, The Institute of Cancer Research, London SW7 3RP, UK. Electronic address: james.larkin@rmh.nhs.uk.
³ Cancer Dynamics Laboratory, The Francis Crick Institute, London NW1 1AT, UK; Renal and Skin Units, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK; Melanoma and Kidney Cancer Team, The Institute of Cancer Research, London SW7 3RP, UK. Electronic address: samra.turajlic@crick.ac.uk.

PMID: 36563660
DOI: 10.1016/j.cell.2022.12.003

Abstract

Combined LAG-3 and PD-1 blockade is an emerging strategy for the treatment of melanoma. Tawbi et al. and Amaria et al. report in The New England Journal of Medicine and Nature respectively on two clinical trials evaluating relatlimab and nivolumab as front-line treatment for metastatic, and resectable, high-risk, node-positive melanoma.

Publication types

Comment

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use
Humans
Ipilimumab
Melanoma* / drug therapy
Melanoma* / pathology
Nivolumab* / therapeutic use

Substances

Nivolumab
relatlimab
Ipilimumab
Antibodies, Monoclonal, Humanized

Grants and funding

29911/CRUK_/Cancer Research UK/United Kingdom